Technical Analysis for BCYC - Bicycle Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -3.70% | |
| Fell Below 50 DMA | Bearish | -3.70% | |
| 20 DMA Resistance | Bearish | -6.17% | |
| 50 DMA Support | Bullish | -6.17% | |
| Inside Day | Range Contraction | -6.17% | |
| Up 3 Days in a Row | Strength | -6.17% | |
| Up 4 Days in a Row | Strength | -6.17% | |
| Up 5 Days in a Row | Strength | -6.17% | |
| Gapped Down | Weakness | -6.17% | |
| 20 DMA Resistance | Bearish | -5.18% |
| Alert | Time |
|---|---|
| Possible NR7 | about 12 hours ago |
| Down 3% | about 12 hours ago |
| Down 2 % | about 13 hours ago |
| Fell Below 10 DMA | about 13 hours ago |
| 10 DMA Support | about 13 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.6701 |
| 52 Week Low | 13.07 |
| Average Volume | 449,750 |
| 200-Day Moving Average | 23.08 |
| 50-Day Moving Average | 24.49 |
| 20-Day Moving Average | 24.82 |
| 10-Day Moving Average | 23.82 |
| Average True Range | 1.32 |
| RSI (14) | 42.86 |
| ADX | 14.46 |
| +DI | 16.74 |
| -DI | 19.07 |
| Chandelier Exit (Long, 3 ATRs) | 24.72 |
| Chandelier Exit (Short, 3 ATRs) | 26.49 |
| Upper Bollinger Bands | 27.50 |
| Lower Bollinger Band | 22.15 |
| Percent B (%b) | 0.24 |
| BandWidth | 21.57 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.11 |
| MACD Histogram | -0.098 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.00 | ||||
| Resistance 3 (R3) | 25.10 | 24.68 | 24.73 | ||
| Resistance 2 (R2) | 24.68 | 24.28 | 24.63 | 24.64 | |
| Resistance 1 (R1) | 24.05 | 24.03 | 23.84 | 23.95 | 24.56 |
| Pivot Point | 23.63 | 23.63 | 23.53 | 23.58 | 23.63 |
| Support 1 (S1) | 23.00 | 23.23 | 22.79 | 22.90 | 22.28 |
| Support 2 (S2) | 22.58 | 22.98 | 22.53 | 22.20 | |
| Support 3 (S3) | 21.95 | 22.58 | 22.11 | ||
| Support 4 (S4) | 21.85 |
